Vaccination strategies for managing brucellosis in Yellowstone bison

Treanor, John J.; Johnson, Joseph S.; Wallen, Rick L.; Cilles, Sara E.; Crowley, Philip H.; Cox, John J.; Maehr, David S.; White, P. J.; Plumb, Glenn E.

doi:10.1016/j.vaccine.2010.03.055

Cited by 30 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, one model for brucellosis estimated a 24 to 66% reduction in seroprevalence in bison over a 30-year period, using an estimation of vaccine efficacy of 0.5 and an estimation of vaccination coverage of 1 to 29% of the population (21). As abortions are the most significant mechanism for horizontal transmission of B. abortus in ruminants, it should be noted that the current study found that booster vaccination reduced abortions by 83%, uterine infection by 60%, and colonization in uterine placentomes by 78% after experimental challenge in comparison to results for control bison.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Dart or Booster Vaccination with Strain RB51 in Protecting Bison against Experimental Brucella abortus Challenge

Olsen

Johnson

2012

Clin Vaccine Immunol

View full text Add to dashboard Cite

This study characterized the efficacy of the Brucella abortus strain RB51 vaccine in bison when delivered by single intramuscular vaccination (hand RB51), by single pneumatic dart delivery (dart RB51), or as two vaccinations approximately 13 months apart (booster RB51) in comparison to control bison. All bison were challenged intraconjunctivally in midgestation with 10 7 CFU of B. abortus strain 2308 (S2308). Bison were necropsied and sampled within 72 h of abortion or delivery of a live calf. Compared to nonvaccinated bison, bison in the booster RB51 treatment had a reduced (P < 0.05) incidence of abortion, uterine infection, or infection in maternal tissues other than the mammary gland at necropsy. Bison in single-vaccination treatment groups (hand RB51 and dart RB51) did not differ (P > 0.05) from the control group in the incidence of abortion or recovery of S2308 from uterine, mammary, fetal, or maternal tissues at necropsy. Compared to nonvaccinated animals, all RB51 vaccination groups had reduced (P < 0.05) mean colonization or incidence of infection in at least 2 of 4 target tissues, with the booster RB51 group having reduced (P < 0.05) colonization and incidence of infection in all target tissues. Our data suggest that booster vaccination of bison with RB51 enhances protective immunity against Brucella challenge compared to single vaccination with RB51 by hand or by pneumatic dart. Our study also suggests that an initial vaccination of calves followed by booster vaccination as yearlings should be an effective strategy for brucellosis control in bison.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Dart or Booster Vaccination with Strain RB51 in Protecting Bison against Experimental Brucella abortus Challenge

Olsen

Johnson

2012

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…However, lack of vaccination against brucellosis may be reason for the existing infection among herds. Vaccination can be suggested for minimizing the infection level among camel herds, however the control remains questionable (Dawood, 2008;Treanor et al, 2010).…”

Section: Journal Of Infection and Molecular Biologymentioning

confidence: 99%

Prevalence of Brucellosis among Camels in District Muzaffargarh, Pakistan

Ullah¹

2015

J. Inf. Mol. Biol.

View full text Add to dashboard Cite

| Brucellosis is an important zoonotic disease of animals and humans. Camel has often been neglected for brucellosis study in Pakistan due to many reasons. A study was conducted to investigate prevalence among camels in district Muzaffargarh. A total of 387 serum samples (300 females; 87 males) were collected and subjected to Rose Bengal plate test (RBPT) and polymerase chain reaction (PCR). Out of 387 samples, 2 (0.51%) were found seropositive by RBPT however, none of them was found positive by PCR. All the seropositive samples came from adult female camels (≥6 years of age) only. Common watering points (e.g. ponds) showed significant association (P<0.05), however, age and sex had non-significant association (P>0.05). The study concluded seroconversion and potential risk factor involved in the spread of brucellosis in camel herds. Routine screening together with public awareness is required to control brucellosis in the area.

show abstract

“…To mitigate livestock disease and reduce human infections, brucellosis vaccination programs are essential. The combination of a livestock vaccination program with culling of infected animals has proven successful to eradicate brucellosis from the majority of states within the US [6, 7]. However, this approach cannot always be adopted by countries unable to provide restitution for the disposed livestock or limited by cultural beliefs [5].…”

Section: Introductionmentioning

confidence: 99%

Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge

Yang

Clapp

Thornburg

et al. 2016

Vaccine

View full text Add to dashboard Cite

There remains a need for an improved livestock vaccine for brucellosis since conventional vaccines are only ~70% efficacious, making some vaccinated animals susceptible to Brucella infections. To address this void, a vaccine capable of evoking protective immunity while still being sufficiently attenuated to produce minimal disease, is sought. In this pursuit, the ΔnorD ΔznuA B. abortus-lacZ (termed as znBAZ) was developed to be devoid of functional norD and znuA B. abortus genes, and to contain the lacZ as a marker gene. The results show that znBAZ is highly attenuated in mouse and human macrophages, and completely cleared from mouse spleens within eight weeks post-vaccination. Producing less splenic inflammation, znBAZ is significantly more protective than the conventional RB51 vaccine by more than four orders of magnitude. Vaccination with znBAZ elicits elevated numbers of IFN-γ+, TNF-α+, and polyfunctional IFN-γ+ TNF-α+ CD4+ and CD8+ T cells in contrast to RB51-vaccinated mice, which show reduced numbers of proinflammatory cytokine-producing T cells. These results demonstrate that znBAZ is a highly efficacious vaccine candidate capable of eliciting diverse T cell subsets that confer protection against parenteral challenge with virulent, wild-type B. abortus.

show abstract

Vaccination strategies for managing brucellosis in Yellowstone bison

Cited by 30 publications

References 29 publications

Efficacy of Dart or Booster Vaccination with Strain RB51 in Protecting Bison against Experimental Brucella abortus Challenge

Efficacy of Dart or Booster Vaccination with Strain RB51 in Protecting Bison against Experimental Brucella abortus Challenge

Prevalence of Brucellosis among Camels in District Muzaffargarh, Pakistan

Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge

Contact Info

Product

Resources

About